Market revenue in 2023 | USD 3,522.8 million |
Market revenue in 2030 | USD 4,135.5 million |
Growth rate | 2.3% (CAGR from 2023 to 2030) |
Largest segment | Pcr-based diagnostics |
Fastest growing segment | NGS DNA Diagnosis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | PCR-based Diagnostics, NGS DNA Diagnosis, In-Situ Hybridization Diagnostics, Microarrays-based Diagnostics |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Beckman Coulter, Bio-Rad Laboratories Inc, Thermo Fisher Scientific Inc, Illumina Inc, Danaher Corp, Hologic Inc, Siemens Healthineers AG ADR, Roche, Qiagen NV, Agilent Technologies Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dna diagnostics market will help companies and investors design strategic landscapes.
Pcr-based diagnostics was the largest segment with a revenue share of 49.93% in 2024. Horizon Databook has segmented the U.S. dna diagnostics market based on pcr-based diagnostics, ngs dna diagnosis, in-situ hybridization diagnostics, microarrays-based diagnostics covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. is expected to be the largest market for DNA diagnostics in North America due to the high cancer prevalence in the country and consequent rapid adoption of diagnostic tests. Some other factors propelling market growth in the country include the increasing prevalence of genetic disorders and the growing emphasis on personalized medicine.
As healthcare shifts toward tailored treatments, genetic testing plays a critical role in identifying the right therapies for patients. In addition, significant technological advancements, an increasing number of FDA approvals for tests, and competition among biotechnology companies are projected to boost the market over the forecast period.
Moreover, according to an article published by the National Library of Medicine in April 2023, over the past two decades, genetic testing has grown in popularity around the world. The U.S. established the Genetic Testing Registry (GTR) in response to the swift advancement of genetic tests, with the aim of facilitating public access to data regarding genetic tests and the associated labs.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. dna diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. dna diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account